Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Edris, Badreddin, Willingham, Stephen, Weiskopf, Kipp, Volkmer, Anne K, Volkmer, Jens-Peter, Mühlenberg, Thomas, Weissman, Irving L, van de Rijn, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716740/
https://www.ncbi.nlm.nih.gov/pubmed/23894705
http://dx.doi.org/10.4161/onci.24452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716740/
https://www.ncbi.nlm.nih.gov/pubmed/23894705
http://dx.doi.org/10.4161/onci.24452

Ejemplares similares